Intraductal Carcinoma of the Prostate Without Invasive Carcinoma on Needle Biopsy: Emphasis on Radical Prostatectomy Findings

2010 ◽  
Vol 184 (4) ◽  
pp. 1328-1333 ◽  
Author(s):  
Brian D. Robinson ◽  
Jonathan I. Epstein
Keyword(s):  
Radical Prostatectomy ◽  
Needle Biopsy ◽  
Invasive Carcinoma ◽  
Intraductal Carcinoma ◽  
Carcinoma Of The Prostate

Presence of intraductal carcinoma of the prostate on needle biopsy as a prognostic factor for prostate cancer in radical prostatectomy patients.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 268-268
Author(s):  
Masashi Kato
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radical Prostatectomy ◽  
Needle Biopsy ◽  
Univariate Analysis ◽  
Intraductal Carcinoma ◽  
Carcinoma Of The Prostate ◽  
High Risk Prostate Cancer ◽  
Gleason Pattern ◽  
Risk Prostate Cancer

268 Background: Intraductal carcinoma of the prostate (IDCP) is seen with widely invasive, biologically aggressive prostate cancer. A recent study has shown this morphologic pattern is useful for prognostication of biochemical recurrence after radical prostatectomy, whereas there is no paper to report biopsy finding of IDCP to be a positive predictor of progression-free survival (PFS) and cancer-specific survival (CSS). Methods: This retrospective study included men with high-risk prostate cancer treated with radical prostatectomy between 1991 and 2005, and we reviewed slides of biopsy samples. Presence of IDCP was defined using previously published diagnostic criteria by a single genitourinary pathologist. Analyzed factors included age, prostate-specific antigen (PSA), clinical T stage, higher biopsy Gleason score (bGS), presence of Gleason pattern five, and IDCP on biopsy samples. Finally, a total of 205 patients with high-risk prostate cancer were entered in our retrospective clinicopathological analysis. Results: Patient mean age was 68. Baseline characteristics included a PSA greater than 20 ng/ml at diagnosis in 122 cases (60%), clinical stage greater than T2 (cT) in 86 (42%), and bGS ³a8 in 150 (73%) in all patients. Follow-up period was 86 months on average. The presence of IDCP on needle biopsy was in 75 (37%). Forty-four patients showed clinical failure, and 20 patients died of the disease. Patients with IDCP showed a higher increased PSA level, higher increased bGS, and more advanced cT than those without IDCP (p < 0.0001). In univariate analysis, IDCP (p < 0.0001), cT (p < 0.0001), bGS (p = 0.0002), and presence of Gleason pattern five (p=0.004) were significantly associated with PFS; IDCP (p < 0.001) and cT (p = 0.02) were significantly associated with CSS. In multivariate analysis, IDCP (p< 0.0001; hazard ratio (HR), 3.574) and cT (p= 0.004; HR, 3.087) were significantly associated with PFS; IDCP (p = 0.001; HR, 8.405) and PSA level (p = 0.0044; HR, 2.920) were significantly associated with CSS. Conclusions: Presence of IDCP on needle biopsy can be a significant predictor of PFS and CSS when analyzing factors of biopsy samples in high risk prostate cancer.

Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded

Pathology ◽  
2020 ◽  
Vol 52 (2) ◽  
pp. 192-196 ◽  
Author(s):  
Hemamali Samaratunga ◽  
Brett Delahunt ◽  
Lars Egevad ◽  
John R. Srigley ◽  
Athanase Billis ◽  
...  
Keyword(s):  
Invasive Carcinoma ◽  
Intraductal Carcinoma ◽  
Carcinoma Of The Prostate ◽  
Aggressive Form

The presence of intraductal carcinoma of the prostate in needle biopsy as a prognostic parameter for prostate cancer patients with distant metastasis.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 237-237
Author(s):  
Masashi Kato ◽  
Toyonori Tsuzuki ◽  
Kyosuke Kimura ◽  
Naoto Sassa ◽  
Yasushi Yoshino ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Needle Biopsy ◽  
Univariate Analysis ◽  
Intraductal Carcinoma ◽  
Prognostic Parameter ◽  
Carcinoma Of The Prostate ◽  
The Core ◽  
Gleason Pattern

237 Background: The presence of intraductal carcinoma of the prostate (IDC-P) is an adverse prognostic factor for prostate-specific antigen (PSA) failure, progression-free survival, and cancer-specific survival (CSS) in localized prostate cancer patients. However, there is no data indicating whether the presence of IDC-P can influence outcome in prostate cancer patients with distant metastasis at presentation. We aimed to evaluate whether IDC-P in needle biopsies is also an adverse prognostic parameter for CSS in prostate cancer patients with distant metastasis. Methods: We retrospectively evaluated 159 prostate cancer patients with distant metastasis who presented at the hospitals that the authors are affiliated with between 2002 and 2012 and reviewed the slides prepared from prostate needle biopsy specimens. Data on the patient age, performance status, clinical T stage, serum PSA, C-reactive protein, alkaline phosphatase (ALP), hemoglobin (Hb), albumin, serum calcium, biopsy Gleason score (> 8 or not), the presence of Gleason pattern 5, the percent of the core involved with cancer, and the maximum percent of a core involved with cancer were analyzed. Patient characteristics were analyzed using the Fisher's exact test. Multivariate Cox proportional hazard regression models were developed to predict CSS. Results: Patient median age was 73 years (range 47–90 years). The median serum PSA was 290 ng/mL (range 4.18–10,992 ng/mL). The median follow-up period was 36 months (range 3–120 months). IDC-P component was detected in 103 (64.8%) patients. There were 82 patients who died of the disease and 6 patients who died of other causes. Using univariate analysis, IDC-P (p = 0.0001), the presence of Gleason pattern 5 (p = 0.005), the percent of the core involved with cancer (p = 0.002), Hb (p = 0.001), and high ALP (p = 0.002) were all shown to be significantly associated with CSS. In the multivariate analysis, only IDC-P (p = 0.016; hazard ratio, 2.187) was significantly associated with CSS. Conclusions: The presence of IDC-P in needle biopsy is a prognostic parameter for CSS in patients with distant metastasis at presentation.

scholarly journals THE DISTRIBUTION OF INTRADUCTAL CARCINOMA OF THE PROSTATE AND ASSOCIATED LESIONS IN THE CANCER FOCI ON RADICAL PROSTATECTOMY SPECIMENS

2014 ◽  
Vol 105 (4) ◽  
pp. 163-171
Author(s):  
Naotaka Sakamoto ◽  
Tomoko Maki ◽  
Masakazu Kawano ◽  
Satoshi Kobayashi ◽  
Takeshi Kobayashi ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
Intraductal Carcinoma ◽  
Carcinoma Of The Prostate ◽  
Associated Lesions

Intraductal Carcinoma of the Prostate Gland With Transmucosal Spread to the Seminal Vesicle: A Lesion Distinct From High-Grade Prostatic Intraepithelial Neoplasia

2007 ◽  
Vol 131 (7) ◽  
pp. 1122-1125 ◽  
Author(s):  
Ronald J. Cohen ◽  
Beverly A. Shannon ◽  
Sydney L. Weinstein
Keyword(s):  
Seminal Vesicle ◽  
Invasive Carcinoma ◽  
Prostate Gland ◽  
Ejaculatory Duct ◽  
Intraepithelial Neoplasia ◽  
Prostatic Intraepithelial Neoplasia ◽  
Intraductal Carcinoma ◽  
High Grade ◽  
Carcinoma Of The Prostate ◽  
High Stage

Abstract Intraductal carcinoma of the prostate (IDC-P) gland represents an intraluminal neoplastic proliferation that is distinct from high-grade prostatic intraepithelial neoplasia (HG-PIN) and almost always coexists with large-volume, high-stage, and high-grade invasive carcinoma. We document an unusual presentation of apparently “early” IDC-P without an aggressive invasive element that, despite being confined to the acinar-ductal system, has gained access to the ejaculatory duct and seminal vesicle by transmucosal spread. This finding confirms that IDC-P, in contrast to HG-PIN, is inherently aggressive and has the ability to spread beyond the prostate gland. In this case, the absence of an aggressive invasive element suggests that IDC-P has most likely evolved within the lumens directly from HG-PIN.

Sign in / Sign up

Export Citation Format

Share Document